跳至主要内容
临床试验/NCT07585331
NCT07585331已完成不适用

Towards Effective, Patient-tailored Anti-plasma Cell Therapies in AL Amyloidosis: Predicting Drug Response and Overcoming Drug Resistance

Fondazione IRCCS Policlinico San Matteo di Pavia1 个研究点 分布在 1 个国家目标入组 250 人开始时间: 2022年1月13日最近更新:

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
250
试验地点
1

研究概览

简要总结

Through an observational clinical study, partly prospective and partly retrospective, based on the collection of clinical data and on in vitro experimental analyses carried out on residual biological samples obtained during routine clinical procedures, it is proposed to identify predictive biomarkers of in vivo response to first-line therapies.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 99 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Biopsy-proven systemic AL amyloidosis
  • No IgM clone
  • No history of anti-plasma cell therapy
  • Diagnostic bone marrow aspiration at ARTC
  • Age > 18 years
  • Willingness to allow use of clinical data and diagnostic leftovers of clinical specimens for research purposes through signing a written informed consent.

排除标准

  • Non-AL amyloidosis
  • IgM clone
  • Previous anti-plasma cell therapy
  • Age <18 years
  • Failure to show willingness to allow use of clinical data and diagnostic leftovers of clinical specimens for research purposes.

研究者

发起方
Fondazione IRCCS Policlinico San Matteo di Pavia
申办方类型
Other
责任方
Principal Investigator
主要研究者

Mario Nuvolone

Principal Investigator

Fondazione IRCCS Policlinico San Matteo di Pavia

研究点 (1)

Loading locations...

相似试验